Condition (MeSH)
Tricuspid Atresia
ClinicalTrials.gov lists 10 trials for Tricuspid Atresia or a narrower condition beneath it. FDA Office of Orphan Products Development has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
10 of the 10 trials are tagged with Tricuspid Atresia itself; the rest are tagged with a narrower condition beneath it.
When did Tricuspid Atresia trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2020 | 1 |
| 2019 | 2 |
| 2011 | 1 |
| 2009 | 2 |
| 2007 | 2 |
| 2004 | 1 |
| 1994 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Tricuspid Atresia trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
| Not applicable | 2 |
| Observational | 3 |
How many Tricuspid Atresia trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Completed | 6 |
| Terminated | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Tricuspid Atresia trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| FDA Office of Orphan Products Development | 1 |
Which drugs are being tested for Tricuspid Atresia? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| SILDENAFIL | 1 |
| DEXMEDETOMIDINE | 1 |
| liothyronine I 131 | 1 |
| Vitamin C | 1 |
| BOSENTAN | 1 |
Which serious adverse events do Tricuspid Atresia trials report? (3)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hypotension | 2 | 1 |
| Bradypnea/Oversedation | 1 | 1 |
| Constipation | 1 | 1 |
Which publications cover Tricuspid Atresia? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Skeletal muscle hemodynamics and endothelial function in patients after Fontan operation. | The American journal of cardiology | 2004 | Yes |
| Univentricular repair: is routine fenestration justified? | The Annals of thoracic surgery | 2000 | Yes |
| Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure. | Journal of the American College of Cardiology | 2013 | No |
| Occlusion of modified Blalock-Taussig shunt after clopidogrel cessation. | The Annals of thoracic surgery | 2012 | No |
| The Fontan procedure: analysis of cohorts and late complications. | Cardiology in the young | 2000 | No |
Prevalence (57)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Tricuspid atresia | Prevalence at birth | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Tricuspid atresia | Prevalence at birth | 1-9 / 100 000 | United Kingdom | GB | Unspecified |
| Tricuspid atresia | Prevalence at birth | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Tricuspid atresia | Prevalence at birth | 1-9 / 100 000 | Norway | Not stated | Unspecified |
| Tricuspid atresia | Prevalence at birth | 1-9 / 100 000 | Belgium | Not stated | Exact |
Showing 5 of 57 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Tricuspid atresia | 1209 | Exact | Orphadata Science knowledge files, Product 1 |
| Tricuspid atresia | 1209 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.